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Organophosphorus nerve agents are amongst the most deadly chemical compounds ever 
synthesized.  Sarin is an organophosphate (OP) ester that irreversibly forms a phosphoester bond 
at the active site of acetylcholinesterase and thereby induces a rapid and lethal cholinergic crisis.  
It remains an active threat to vulnerable civilian populations due to its ease of synthesis and 
known use by rogue nations and terrorist groups.  Death is the most extreme consequence of sarin 
toxicity.  Current treatments fail to provide protection against progressive cognitive impairments 
years after mild exposure.  Q-VD-OPh is an in-vivo caspase inhibitor with potent anti-apoptotic 
and anti-inflammatory properties.  In this pilot study, adult male C57BL/6J mice were 
subcutaneously injected with 0.5 LD50 sarin followed by an intraperitoneal injection of 20 mg/kg 
Q-VD-OPh.  Mice were sacrificed at a two-day time point followed by MALDI imaging and 
immunohistochemical analysis of brain sections.  Protein mass spectra of tissue sections 
subjected to organic washes yielded an increase in signal sensitivity compared to untreated 
sections.  A non-significant upward trend in GFAP expression was observed in sarin treated 
animals in contrast to Q-VD-OPh animals.  Statistically significant downward trends in nuclear 
NF-κB/p50-50 expression were observed in sarin treated animals in contrast to Q-VD-OPh 
animals.  These trends open a window to innovative research paradigms that extend beyond the 
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I.  Introduction 
The History of Sarin 
Sarin (GB; O-isopropyl methylphosphonofluoridate) is among the most toxic nerve 
agents developed in the 20th century.  Sarin derived its name from the four German scientists 
accredited with its synthesis in the 1930’s:  Schrader, Ambros, Rudriger, and van der Linde 
(Sidell et al., 2008).  In addition to sarin, the other nerve agents ie., tabun, cyclosarin, and soman 
were developed in Germany during the same period (Popov et al., 2008).  Designated by NATO 
as the G-agents, they were originally developed for use as OP insecticides (Costa, 2006).  
However, German military personnel quickly recognized their use as chemical warfare agents 
(CWAs) after scientists reported symptoms of pupil eye constriction and discomfort when 
working with them (Newmark, 2004). 
While large stockpiles of sarin were produced by Germany during the WWII era, it was 
first used as a CWA during the Iran-Iraq war of the 1980’s (Hurst et al., 2007).  Approximately 
45,000 and 120,000 Iranian casualties were the subject of sarin attacks by Iraqi forces (Newmark, 
2004).  During the Gulf war of the early 1990’s, an Iraqi munitions dump was destroyed exposing 
more than 100,000 U.S. troops to sarin (Chao et al., 2010).  Gulf war veterans reported symptoms 
of drowsiness, short-term memory loss, attention deficits, irritability, confusion, and depression 
(Abu-Qare and Abou-Donia 2002; Chao et al., 2010; McCauley et al., 2001).  Studies of Gulf war 
veterans four years post exposure suggested a greater risk for brain cancer deaths than unexposed 
veterans (Bullman et al., 2005).  White and colleagues evaluated short-term memory 






(White, 2001).  They found that veterans exposed to sarin exhibited declines in 
neuropsychological performances than those that were not exposed (White et al., 2001). 
Sarin is highly toxic and effective through multiple routes of exposure (Figure 1).  Even 
though the use of OPs was outlawed by the 1997 Chemical Weapons Warfare Convention, their 
ease of synthesis and known use by terrorist groups continues to pose a security threat (Popov et 
al., 2008; Trapp, 2006).  For instance, in Japan of 1994 the Aum Shinrikyo religious group 
attacked 600 residents of Matsumoto city killing seven and injuring 58 (Morita et al., 1995).  In 
the following year on March 20, Aum members released liquid sarin on five separate lines of the 
Tokyo subway killing 12 people and causing an estimated 5,000 to seek medical attention 
(Okumura et al., 1998). 
 
Figure 1:  Chemical structure of sarin (C4H10FO2P).  Sarin is colorless, odorless, and the most 
volatile of all the nerve agents.  The toxicological action of sarin is due to its covalent bond 
formation with the active serine site of acetylcholinesterase.  Toxic effects can occur by ingestion, 
inhalation, and cutaneous exposure with the liquid and or vapors. 
Mechanisms and Effects of OP Toxicity 
Sarin is an OP ester that irreversibly forms a phosphoester bond at the active site of 
acetylcholinesterase (AChE) thereby preventing the degradation of the neurotransmitter 
acetylcholine (ACh).  The active site of AChE is a catalytic pocket composed of the amino acids 





glutamate residues position the OP in place while the serine residue forms a partial covalent bond 
with the fluorophosphate group (Figure 2) (Majumdar et al., 2006). 
 
Figure 2:  Initial binding of sarin to AChE.  Note the alkyl group still bound.  
This forms a partially unstable phosphorylated enzyme that undergoes a spontaneous time-
dependent dealkylation reaction known as aging (Jokanovic, 2009).  It is only during this brief 40 
min period that the OP can be removed from the enzyme.  Eventually, the alkyl group leaves 
forming a highly stable AChE phosphoester resistant to current recovery therapies (Figure 3) 
(Abou-Donia, 2003; Goodman et al., 2006; Schier and Hoffman, 2004).   
 The permanent inhibition of AChE causes a rapid accumulation and subsequent 
overstimulation of ACh at neuroeffector junctions in the central and peripheral nervous system 
(CNS and PNS) (McDonough and Shih 1997).  In the cholinergic system, ACh is released in 
response to nerve stimulation and binds to post synaptic nerve receptors to elicit a biological 
effect (Platt and Riedel, 2011).  This effect is rapidly terminated through the subsequent cleavage 
of ACh by the catalytic serine of AChE allowing the postsynaptic nerve to return to its original 





nerves to be in a state of constant excitement resulting in acute symptoms:  convulsions, seizures, 
paralysis of motor function, excessive mucosal lacrimations, and death primarily from respiratory 
failure (Jokanovic and Kosanovic 2010; Moretto et al., 2011). 
 
Figure 3:  Sarin aged AChE.  The loss of an alkyl group results in a permanently inhibited 
enzyme. 
Current Treatment for OP Poisoning  
 The current treatment for sarin exposure is available to military and emergency response 
personnel and is termed the CANA-MARK I kit (Sidell et al., 2008).  The CANA-MARK I kit is 
composed of three injectable drugs: 
1) Atropine-relieves the symptoms of excessive ACh stimulation at muscarinic 
receptors (Sidell et al., 2008).  
2) 2PAM (2-pyridine aldoxime methyl chloride)-regenerates AChE by phosphoryl 
group removal but only when the alkyl group is still bound (Sidell et al., 2008). 






It is crucial to administer CANA-MARK I treatments immediately after OP exposure as these 
treatments cannot rescue permanently bound OP-AChE adducts.  Even if the current 
prophylactics are given within a 40-minute period, it is inevitable that victims of OP exposure 
may develop prolonged and progressive neuroinflammation and neurodegeneration (Doctor and 
Saxena 2005).  Sarin is still an active threat to military and civilian populations.  While military 
personnel are readily equipped with CANA-MARK I kits, the general population must rely on 
emergency response personnel to administer treatment in a densely populated area.  The 
likelihood that all victims receive treatment in a sarin-induced terrorist attack is unlikely since 
first responders must navigate through a heavily populated area of mass panic, identify victims 
needing immediate care, and administer treatments with a narrow therapeutic time window.  
Therefore, those that survive sarin exposure represent a vital proportion of the population at risk 
of developing long-term adverse neurodegenerative disorders (Doctor and Saxena 2005).  Hence, 
the ability to attenuate OP induced neuronal cell death and inflammation would establish as a 
vital improvement over current CANA-MARK I treatments. 
Effects of OP Toxicity in Specific Brain Regions 
 While sarin causes death and acute cholinergic toxicity in small vicinities, it largely 
causes chronic neurotoxic symptoms to individuals within a broader exposure radius.  The 
delayed onset of neurotoxic symptoms from sarin exposure results from contact to large, acutely 
toxic or small subclinical doses (Jamal, 1997).  Clinical symptoms persist from weeks to years 
resulting in delayed type neurological and neurobehavioral abnormalities:  chronic headaches, 
short-term memory loss, fatigue, attention deficits, depression, anxiety, confusion, and 
personality changes (Grauer et al., 2008; Jaga and Dharmani 2007; Yanagisawa et al., 2006).  
Several regions within the brain inclusive of the dendate gyrus and CA2-CA3 (Cornu Ammonis 
Region II-III) subfields of the hippocampus, piriform cortex, amygdala, and hypothalamus show 





to OP exposure (Figure 4) (Spradling et al., 2011).  Neurons in these brain regions are associated 
with mood, judgment, emotion, learning, and memory, e.g., granular, pyramidal, and 
magnocellular neurosecretory cells (Dickerson and Eichenbaum 2010; Sawchenko and Swanson 
1990). 
 There are numerous examples of OP-induced neuronal degenerations in brain regions 
correlating to learning and memory deficits.  For instance, a study by Kilburn (1999), in patients 
exposed to the OP chlorpyrifos demonstrated neuropsychological abnormalities in verbal 
memory, cognitive function, and mood.  Furthermore, rats given a dermal application of 0.1 
mg/kg chlorpyrifos developed deficits in sensorimotor function (Abou-Donia et al., 2003).  
Additionally, neuropathological modifications following soman exposure were observed in the 
hippocampus and hypothalamus regions of rat brains (Petras, 1994).  Petras and colleagues also 
noted axonal degeneration was not dependent on the initiation of seizures in rats following acute 
soman exposure (1994).  Neurodegeneration was also present in the dendate gyrus and CA1-CA3 
subfields in rats 24 hours following a 100 μg/kg intramuscular injection of sarin (Abdel-Rahman 
et al., 2002).  Rats that survived a 95 μg/kg injection of sarin exhibited persistent lesions in the 






Figure 4:  Brain Regions of Interest:  Dendate gyrus and CA2-CA3 subfields of the 
hippocampus, piriform cortex, amygdala, and hypothalamus.   
 The delayed symptoms of acute or subclinical doses of sarin indicate that OPs’ exert their 
toxicity through neuroinflammatory and neurodegenerative processes.  For instance, the presence 
of inflammatory cytokines, e.g., IL-6, IL-10, IL-1β, and TNF-α have been noted in sub-lethal 
exposures to organophosphates (Spradling and Dillman III 2011).  Brain damage in animal 
models exposed to nerve agents resulted in the increased expression of proinflammatory 
cytokines, deceased or degenerating neurons, and activated microglia and astrocytes (Collombet, 
2011).  The recruitment of these inflammatory factors indicates that the toxicity of sarin-induced 
neuropathies is potentiated by neuroinflammation.  Excessive accumulation of reactive oxygen 





protease) induction, and DNA fragmentation that ultimately end in apoptosis.  This notion is 
supported by evidence that sub-lethal doses of OPs generate ROS and are thereby accountable for 
neurodegenerative processes (Segura-Aguilar and Kostrzewa 2004).  In addition, Abdel-Rahman 
and colleagues demonstrated the apoptotic degeneration of adult male rat brain hippocampal 
neurons at a 24-hour time point following a sub-lethal dose of sarin (2002).  Additionally, while 
rats treated with a sub-toxic dose of sarin did not show evidence of neurohistopathological lesions 
at a 30-day time point, they eventually exhibited apoptotic neuropathies one year after dosing 
(Abdel-Rahman et al., 2002).  Recent evidence indicates that OP’s are responsible for the 
amplification of apoptotic events that cause the progressive loss of neurons (Tebourbi et al., 
2011).  The activation of a caspase-induced cell death pathway indicates that the toxicity of sarin-
induced neuropathies is also potentiated by neurodegeneration.  It is worthwhile to investigate the 
effects and mechanisms of sarin-induced neuroinflammation and neurodegeneration in order to 
pursue the development of optimal neuroprotective agents that would provide new avenues for 
targeted therapeutic drug design against nerve agent attacks in civilization and tactical warfare. 
Secondary Targets of Chronic OP Exposure   
 It is well known that lethal doses of OP’s inhibit AChE by formation of a phosphoester at 
a serine residue.  Elucidation of this mechanism centered on the observation that symptoms of 
cholinergic inhibition are most noticeable and life threatening.  This is because the catalytic 
activity of AChE transpires at a plethora of synaptic junctions throughout the peripheral and 
central nervous system that vitally depend on the breakdown of ACh in order to operate normally.  
However, it became perplexing when sub-lethal doses of OPs caused no obvious cholinergic 
symptoms yet were linked to illnesses of delayed neuropathies such as memory loss, depression, 
cognitive impairment, and debilitating motor skills (Ergun et al., 2008; Masoud et al., 2011).  The 
absence of cholinergic inhibition yet the delayed expression of neurodegenerative processes led to 





 The brain is particularly susceptible to OP poisoning because it requires high amounts of 
oxygen, large quantities of ATP, possesses significant amounts of peroxidizable lipids, and 
contains a low quantity of antioxidant enzymes e.g., glutathione (El-Demerdash, 2011).  Sarin is a 
lipophilic OP that readily crosses the blood brain barrier (BBB) and irreversibly binds to serine 
hydrolases leading to the accumulation of endogenous substrates that initiate a cell death cascade 
(Carter et al., 2011).  Serine hydrolases belong to a large superfamily and mainly include serine 
proteases, intracellular and extracellular lipases, thioesterases, phospholipases, and 
cholinesterases (including AChE) (Simon and Cravatt 2010).  All of these enzymes hydrolyze 
their substrates at a nucleophilic serine residue within a catalytic triad site.  For instance, 
lysolecithin is a major phospholipid in glial cells that is metabolized by NTE-LysoPLA 
(Neuropathy Target Esterase-Lysophospholipase) (Quistad et al., 2003).  Inhibition of NTE-
LysoPLA with OPs led to elevated levels of lysolecithin and subsequent demyelination of 
neurons (Casida and Quistad 2004).  Since hundreds of serine hydrolases are expressed in the 
human proteome, OP inhibition with secondary targets may alter downstream effectors and 
markers that govern neuroinflammatory and neurodegenerative processes (Figure 5) (Thompson 
et al., 2010). 






Figure 5:  Secondary targets of OP exposure.  AChE is one of many hundreds of serine 
hydrolases and other secondary targets altered after OP exposure.   
Mechanism of Apoptosis 
 Apoptosis is an operational process of cell death distinguished by lack of an 
inflammatory response, caspase activation, substrate cleavage, DNA fragmentation 180bp’s in 
length, plasma membrane blebbing, and formation of apoptotic bodies that are phagocytized by 
resident microglia (Van Cruchten and Van Den Broeck 2002; Trump et al., 1997).  There are two 
types of caspases that mediate apoptosis i.e., initiator caspases 8, 9, and 10 and effector caspases 
3, 6, and 7 (Inoue et al., 2009).  Initiator caspases cleave inactive pro-forms of effector caspases 
that in turn cleave protein substrates within the cell triggering the apoptotic process.  There are 
two main apoptotic pathways in humans that arise from extrinsic or intrinsic cellular signals 
(Figure 6) (Brown, 2004).  The extrinsic pathway is characterized by caspase 8/10 activation after 
cell surface death receptor ligation with TNF-α (Fulda and Debatin 2006).  The intrinsic pathway 





cytosol (Fulda and Debatin 2006).  Both pathways converge at caspase 3, even though the 
characterization of the extrinsic pathway is not distinguished by the cleavage of this effector 
caspase.   
 
Figure 6:  Extrinsic and intrinsic pathways of apoptosis. 
Proinflammatory and Anti-inflammatory NF-κB Activation Pathways 
 NF-κB (nuclear factor kappa-b) is expressed in neurons and glial cells in the CNS and 
plays vital roles in inflammatory and immunological reactions (Mefferet and Baltimore 2005; 
O’Neill and Kaltscmidt 1997).  Inactive NF-κB dimers are localized in the cytoplasm by IκB 
precursors in nonstimulated cells (Nishikori, 2005).  Active NF-κB dimers are comprised of a 
variety of Rel family proteins and are liberated from IκB precursors through IκB phosphorylation 
in stimulated cells (Ghosh et al., 1998; Singh and Jiang, 2004).  There are two active NF-κB 
dimers responsible for the nuclear transcription of proinflammatory and anti-inflammatory genes:  





(Singh and Jiang, 2004).  Thus, the NF-κB p50/p65 heterodimer is anti-inflammatory and pro-
apoptotic whereas the NF-κB/p50-p50 homodimer is proinflammatory and anti-apoptotic.     
 
Figure 7:  Proinflammatory and anti-inflammatory pathways of activated NF-KB dimers.  
Nuclear translocation of the NF-KB/p50-50 homodimer induces transcription of anti-
inflammatory cytokines whereas nuclear translocation of the NF-KB/p50-65 heterodimer induces 
transcription of proinflammatory cytokines.  
 Since apoptosis is characterized by lack of an inflammatory response, it is reasoned that 
an environment promoting NF-KB/p50-p50 activation may be triggered after initial exposure to 
sub-lethal amounts of OPs.  However, neuroinflammation has been reported in animal models 
exposed to OP’s.  Therefore, it is also reasoned that an environment promoting NF-KB/p50-p65 





unknown if either neurodegeneration or neuroinflammation predominantly occur following sub-
lethal OP exposure, it is unknown if the nuclear expression of NF-κB/p50-p50 stained cells will 
show an upward, downward, or no trend at all in sarin treated animals. 
 An endpoint of OP induced neuropathies results in the axonal degeneration of neurons 
resulting in the formation of a glial scar around the damaged tissue.  Astrocytes are a subtype of 
glial cell in the CNS that is star-shaped with many filaments that envelope neurons and their 
synapses (Sofroniew and Vinters 2010).  Astrocytes express the intermediate filament GFAP 
(glial fibrillary acidic protein) and upon activation increase its expression resulting in the 
proliferation of these cells around wounded areas in order to prevent additional damage to 
adjacent tissues (Sofroniew and Vinters 2010).  Hence, GFAP expression is a marker for neuronal 
injury.  In this study, we expect to see a greater number of GFAP stained cells in sarin treated 
animals.   
Exploration of Endogenous Biomarkers  
 OP esters covalently bind and inhibit enzymes of the serine hydrolase family, including 
AChE (Thompson, 2010).  Other than OP-AChE inhibition, the connection between OP-ChE 
inhibition and the resulting downstream cellular/toxic outcomes have not been established 
(Rubino et al., 2009).  Matrix-assisted laser desorption/ionization (MALDI) imaging has emerged 
as a powerful tool to quantify biomarkers in-situ by offering high-throughput, fingerprinting, and 
identification of peptides after formulation with a matrix (Stoeckli et al., 2001).  The matrix 
consists of organic solvents mixed with water in order to dissolve hydrophobic and hydrophilic 
molecules in tissue.  Typically, a matrix co-crystallizes with analytes in tissue after the solvents 
evaporate during the application procedure.  The matrix absorbs the destructive energy of the 
laser and transfers its charge to peptides resulting in the formation of quasimolecular ions (Read, 





sodium [M+Na]+, or a removed proton [M+H]- (Levsen et al., 2007; Stoll and Rollgen 1981).  
Before the development of MALDI imaging, quasimolecular ions were displayed as a mass 
spectrum, a histogram of peptide abundance versus its mass to charge (m/z) ratio.  With MALDI 
imaging, a mass spectrum is displayed in addition to a representative image of its spatial 
distribution within whole body tissue sections (Reyzer and Caprioli 2007).   
 MALDI mass spectrometers are operational in either linear mode or reflector mode and 
use time of flight (TOF) hardware to determine a peptides m/z ratio (Domon and Aebersold 
2006).  In linear mode, ions are pulsed by a laser into an ion source and accelerated by an electric 
field into a linear flight tube onto a detector (Figure 8) (Rappsilbera et al., 2003).  This allows 
ions with a smaller mass to charge ratio to reach the detector faster than ions with a greater mass 
to charge ratio.   
 
Figure 8:  MALDI-TOF linear mode. 
However, in many instances the spectra produced in linear mode produces broad peaks with poor 





slight differences in ionization energy (Weston, 2010).  Hence, ions of the same mass reach the 
detector at different speeds when they should reach the detector at the same speeds.  In reflector 
mode, ions are accelerated by an electric field into a linear flight tube to an optic mirror that 
subjects ions to a uniform repulsive field (Figure 9) (Muddiman et al., 1997).  The repulsive field 
redirects their time of flight through a reflector flight tube onto a detector (Flensburg et al., 2004).  
Thus, ions with greater ionization energy will penetrate deeper into the repulsive field and hence 
will take longer to reach the detector.  This compensates for the initial energy spread of ions of 
the same mass and improves the resolution of a mass spectrum (Kurnosenko and Moskovets 
2010). 
 
Figure 9:  MALDI-TOF reflector mode. 
 This study will employ the principles of MALDI imaging to explore unknown 
biomarkers in whole brain tissue sections of mice in control and treated groups.  A broad range of 
low molecular weight peptides will be ionized in reflector mode with a α-cyano-4-





suitable matrix for the detection of peptides with a molecular mass ranged between 500-3000 Da 
with a 0.5 Da precision (Fournier et al., 2003). 
Potential Therapy:  In-vivo Caspase Inhibitor Q-VD-OPh 
 During the last decade, the understanding of apoptosis has focused scientists on 
formulating inhibitors that prevent caspase activation (Barut et al., 2005; Li et al., 2000).  Broad-
spectrum caspase inhibitors permeate the cell membrane and alkylate the active cite cysteine of 
caspases and irreversibly block apoptosis by preventing caspase activation, substrate cleavage, 
and DNA ladder formation (Caserta et al., 2003).  However, many of these caspase inhibitors are 
conjugated to toxic fluoromethylketone (FMK) groups that limits there use in animal studies 
(Chauvier et al., 2006; Van Noorden, 2001).  For instance, FMK inhibitors require doses greater 
than 50 μM to be effective but are also toxic at these doses as well (Brown, 2004).  In contrast to 
FMK type inhibitors, Q-VD-OPh (Quinolyl-valyl-O-methylaspartyl-[2,6 difluorophenoxy]-
methyl ketone) was demonstrated to be non-toxic and highly effective at doses as low as 5 μM in 
tissue cultures (Caserta et al., 2003).   
 Due to its safety and potency in-vitro, applications of Q-VD-OPh in-vivo have also 
demonstrated it to be nontoxic and effective as well.  In animal models of stroke and CNS 
damage, Q-VD-OPh prevented neurodegeneration and restrained neuroinflammatory responses 
(A. Çolak et al., 2009; Abrahamson et al., 2006; Braun et al., 2007; Renolleau et al., 2007).  
Furthermore, Q-VD-OPh has demonstrated to cross the BBB and inhibit all major apoptotic 
pathways in humans, caspase 8/10, and caspase 9/3 (Caserta et al., 2003).  Mice injected with an 
intraperitoneal dose of 120 mg/kg Q-VD-OPh did not show evidence of toxicity (Melnikov et al., 
2002).  Presently, the recommended dose for in-vivo applications is 20 mg/kg (Caserta et al., 
2003). 
 Q-VD-OPh consists of the amino acids valine and aspartic acid, coupled to a C-terminal 





provide a non-toxic leaving group and the quinolyl group may act as a peptidomimetic thereby 
elevating the active intracellular concentration of inhibitor present (Southerland et al., 2010).  
Due to its nontoxcity, potency, and membrane permeability, the current study will examine the 
effectiveness of Q-VD-OPh against neuroinflammation and neurodegeneration in the brains of 
mice exposed to a single subcutaneous injection of the nerve agent sarin. 
 
Figure 10:  Chemical structure of Q-VD-OPh. 
Use of CBDP:  A Carboxylesterase Scavenger 
 Caboxylesterase is an endogenous chemical scavenger that inactivates OPs.  Rodents 
have a high level of carboxylesterase compared to humans that inactivates OPs before they can 
interact with AChE to produce the classical symptoms of OP poisoning (Clement and Ernhardt 
1990).  Cresylbenzodioxaphosphorin oxide (CBDP) is a carboxylase scavenger that inhibits 
excess rodent carboxylesterase and efficiently increases rodents’ susceptibility to OP poisoning, 
making their exposure at low doses more representative of human exposure (Masson, 2011).  
Preliminary work has demonstrated that a dose of 1.5mg/kg CBDP specifically blocks 
carboxylesterase, and potentiates the response of C57BL/6J mice to sarin without causing toxicity 








Hypothesis and Specific Aims 
 The large body of evidence indicating that the current treatment regimes of OP poisoning 
fail to prevent neuroinflammation and neurodegeneration and the relatively novel concept that Q-
VD-OPh is potentially useful as an in-vivo neuroprotectant beyond a 40 minute administration 
window lead to the development of the following hypothesis:  Sarin-induced, prolonged or 
progressive CNS neuro-inflammatory responses, and neurodegeneration can be attenuated by use 
of an in-vivo caspase inhibitor, Q-VD-OPh.  In order to study the possible neuroinflammatory and 
neurodegenerative pathologies following sub-lethal OP exposure, and whether these pathologies 
could be attenuated by therapeutic use of Q-VD-OPh, we divided these pathologies into three 
specific aims.   
Specific Aim 1 
Establish neuroinflammatory and neurodegenerative markers of sarin exposure.  
Specific Aim 2 
Test the hypothesis that Q-VD-OPh can attenuate progressive sarin-induced neurodegeneration. 
Specific Aim 3 











II. Materials and Methods 
Animals 
An AAALAC (Association for the Assessment and Accreditation of Laboratory Animal 
Care) standard facility held adult male C57BL/6J mice on a 12-hour light/dark cycle with open 
access to a standard pellet diet and water.  Mice were acclimated to their environment for seven 
days and subjected to three days of handling before dosing.  Mice were subjected to a dosing 
sequence that mimics chronic OP toxicity in humans via the injection of 1.5 mg/kg CBDP 30 min 
before a 0.5 LD50 injection of sarin.  To ensure that our caspase inhibitor provided 
neuroprotection beyond the limitations of CANA-MARK-1 treatments, mice received a 20 mg/kg 
injection of Q-VD-OPh 40 minutes after sarin injections.  Mice were divided into the following 
groups and classified according to the treatments administered: 
1) Saline:  Animals that received a glycol-saline-saline injection series. 
2) CBDP:  Animals that received a CBDP-saline-saline injection series. 
3) Sarin:  Animals that received a CBDP-sarin-saline injection series. 
4) Q-VD-OPh:  Animals that received a CBDP-sarin-Q-VD-OPH injection series. 
Drugs  
CBDP was diluted in propylene glycol and 5% ethanol to a dose of 1.5 mg/kg.  Sarin 
(USAMRICD, Aberdeen Proving Ground, MD) was obtained as a 1.9 mg/ml stock solution and 
subsequently diluted in 0.9% saline to a dose of 46 µg/kg (0.5 LD50).  Q-VD-OPh was diluted in 
0.9% saline to a dose of 20 mg/kg.  The first two treatments of an injection series were dispensed 
subcutaneously whereas the third treatments of an injection series were dispensed 






Tissue Collection and Sectioning  
 Mice were sacrificed followed by the collection of brain tissue.  Tissue was flash frozen 
in isopentane for 30 seconds and stored at -80°C until sectioned. The brains were mounted on a 
cryocassette but not completely covered with tissue freezing medium (Triangle Biomedical 
Sciences, Durham, N.C.) in order to keep limited tissue sections freely exposed to the cryotome.  
This ensured that polymers within the tissue-freezing medium did not suppress analyte signals 
during analysis with the mass spectrometer.  Brains were coronally sliced on three different 
cryotomes:  Leica CM3050, Thermo Shandon Cryotome E, and a Reichert-Jung Cryocut 1800.  
Tissue was sliced at a thickness of 12μm at -20°C throughout brain regions inclusive of the 
dendate gyrus, CA2-CA3, piriform cortex, amygdala, and hypothalamus between 0-5 mm rostral 
from the intraural line.  Brain regions were selected using landmarks in The Mouse Brain in 
Stereotaxic Coordinates (Paxinos and Franklin, 2008), and confirmed after the consultation of 
two experts.  Sections for immunofluorescent staining were thaw mounted on UltraStick slides 
(Gold Seal Products, Portsmouth, NH), placed in a desiccator for 45 min at 21°C, and then stored 
at -20°C.  Sections for MALDI Imaging were thaw mounted on conductive glass slides (Bruker 
Corporation, Bremen, Germany) and placed in a desiccator for 45 min at 21°C.  Sections were 
then washed in a 70% isopropanol solution followed by a 95% isopropanol solution for 30 
seconds each.  Afterwards, sections were dried in a desiccator for 45 min at 21°C and then stored 






GFAP Immunofluorescent Staining 
Tissue sections were dried in a desiccator for 45 min at 21°C.  A liquid repellent PAP pen 
(Daido Sangyo Company, Tokyo, Japan) was used to draw boundaries around sections and let dry 
for 10-15 min.  Tissue sections were fixed with 2% paraformaldehyde in 1XPBS + 0.2% Triton 
X-100 (TX-100) for 30 min at 4°C in a moist chamber.  A moist chamber is a plastic tupperware 
container with a tight lid where slides are laid upon pairs of glass rods placed on absorbent paper 
soaked with distilled water.  All incubations at 4°C were performed in a moist chamber.  Sections 
were washed 5 times in 1XPBS for 5 min each at 21°C.  Sections were then blocked with 10% 
normal goat serum (NGS) in 1XPBS for 1 hr at 4°C.  Next, sections were incubated with primary 
rabbit anti-GFAP (Invitrogen, Camarillo, CA) at a 1:400 dilution in 10% NGS + 1XPBS for 1 hr 
at 4°C.  For a negative control, serial sections were incubated with normal rabbit serum (NRS) 
diluted 1:400 in 10% NGS + 1XPBS for 1 hr at 4°C.  Afterwards, sections were washed 5 times 
in 1XPBS for 5 min each at 21°C.  Sections were then incubated with secondary biotin-SP-
conjugated donkey anti-rabbit (Jackson Immunoresearch Laboratories, West Grove, PA) at a 
1:200 dilution in 10% NGS + 1XPBS for 1 hr at 4°C.  Next, sections were washed 5 times in 
1XPBS for 5 min each at 21°C.  Afterwards, sections were incubated with Cy3-conjugated 
streptavidin (Jackson Immunoresearch Laboratories, West Grove, PA) at a 1:200 dilution in 
1XPBS for 1 hr at 4°C.  Sections were then washed 3 times in 1XPBS for 5 min each at 21°C.  
Next, sections were incubated with Hoechst stain 33342 (Intergen) at a 1:200 dilution in 1XPBS 
for 5 min at 21°C.  Hoechst stain labels all nuclei and allows for the visualization of brain 
structures.  Afterwards, sections were washed once in 1XPBS for 5 min at 21°C.  Then, slides 
were mounted with gel mount mounting medium (Biomedia, Foster City, CA) using Gold Seal® 







NF-κB Immunofluorescent Staining 
 Tissue sections were stained for NF-κB as described above for GFAP staining with the 
exception of using primary rabbit anti-NF-κB p50 (Santa Cruz Biotechnology, Santa Cruz, CA) 
diluted 1:300. 
Image Capture 
 Fluorescently stained sections of the dendate gyrus, CA2-CA3 sub-field, piriform cortex, 
amygdala, and hypothalamus brain regions were viewed on a Leica DMR microscope equipped 
with a Leica DFC 310 FX camera.  Exposure times were set for each brain region at an optimal 
magnification for each stain to ensure the image was not over or under saturated with fluorescent 
light.  Images were respectively captured under the LP 590 (red) and the BP 470/40 (UV) 
suppression filters to ensure UV light did not bleach Cy-3 labeled cells.  Individual images were 
layered with Leica Application Suite software v.3.7.0 (Leica Microsystems, Heerbrugg, 
Switzerland) to create a single image overlay of Cy-3 GFAP and NF-κB stained cells and 
Hoechst 33342 stained nuclei.  NF-κB and GFAP stained sections were captured at 40X and 20X 
magnifications respectively. 
MALDI Imaging 
 Tissue sections were thawed in a desiccator for 45 min at 21°C.  Then, three white out 
marks were spotted around the sections.  The white out marks serve as teach points that are 
visible on the optical image and underneath the matrix layer in the camera optic.  An optical 
image of the sections was captured with an Epson Perfection V200 photo office scanner.  The 
matrix solution (10 mg/ml) was prepared by dissolving CHCA (Acros Organics, Morris Plains, 
NJ) in 50% acetonitrile (ACN), 0.2% trifluoroacetic acid (TFA), and brought to volume with 
water.  Then, sections were placed in a fume hood and the matrix solution was applied with a 





Each spray cycle was a single application of matrix that lasted between 1-2 seconds in order to 
build an even matrix layer of extracted peptides.  Spray cycles were discontinued when 90% of 
the tissue was covered in matrix crystals.  Afterwards, the sections were placed in a desiccator for 
45 min at 21°C.  Dried sections were mounted on a MTP slide adapter (Bruker Corporation, 
Bremen, Germany) and loaded into a Bruker Autoflex III equipped with a SmartBeam laser and 
an electrostatic reflector.  Protein mass spectra ranging from 1000 to 5000 m/z were acquired 
from each spot in an automated fashion in linear positive-ion mode using a delay time of zero 
nanoseconds.  Peptides were ionized with a pulsed nitrogen laser set at 79% intensity and 
accelerated with a 7.95kV electrical field onto a detector suppressing up to 50 Da.  Ions were 
identified at a sample rate of 2.00 GS/s with a 20X detector gain set at 100mV.  All spectra were 
the sum of 200 individual laser shots collected in 100-shot increments within each matrix spot.  
The laser position was moved within the spot between each incremental step.  Spectra were 
processed using fleximaging v.2.1 (Bruker Corporation, Bremen, Germany) that include24d 
baseline correction and alignment.  Evaluation of results included the presence or absence of 
signals and intensity of background.    
Data/Statistical Analysis 
 Image overlays were opened in ImageJ v.1.45 and positively labeled cells within defined 
areas were counted using the cell counter plug-in.  Areas for GFAP stained dendate gyrus, CA2-
CA3 sub-field, piriform cortex, amygdala, and hypothalamus regions were 641 x 479 μm (Figure 
11).  Areas for NF-κB p50 stained CA2-CA3 sub-field, piriform cortex, amygdala, and 
hypothalamus regions were 321 x 240 μm (Figure 12).  Counts from one section from each 
animal were averaged to obtain a mean cell count for each region.  Cell counts were uploaded 
into Graphpad Prism v.5.01 where one way ANOVA was used to evaluate the overall 





different sizes) was used to test for individual group differences.  All values are reported as mean 
± standard deviation.  P-values < 0.05 were accepted as statistically significant. 
 
Figure 11:  Representative image of a GFAP labeled tissue section (12 μm) assessed for cell 
counting.  Only filament bearing cells showing their nucleus in the plane of section (641 x 479 








Figure 12:  Representative image overlay of a NF-κB/p50-p50 and nuclei labeled tissue section 
(12 μm) assessed for cell counting.  A primary NFκB/p50 antibody was used to label the inactive 
NFκB/p105 precursor complex that holds the NFκB/p50-50 dimer in the cytoplasm and liberated 
NF-κB/p50-p50 in the nucleus.  Cytoplasmic NFκB/p50-50 was characterized when it did not 
overlap nuclei (single-headed arrow).  Nuclear NF-κB/p50-p50 was characterized when it did 
overlap nuclei (double-headed arrow).  Characterized cells were recorded in a 321 x 240 μm 







Chemical Treatment of Tissue Sections for MALDI Imaging 
 MALDI Imaging is a technique that allows for the study of the spatial arrangement of 
molecules within biological tissues.  A typical preparation procedure involves the application of a 
matrix spray onto thaw mounted tissue sections that are then dried and introduced to the vacuum 
inlet of the mass spectrometer; where a laser generates quasimolecular ions displayed as images 
(Figure 13).   
 
Figure 13:  General methodology developed for the spatial analysis of tissue by MALDI Imaging 
mass spectrometry. 
The detection of neuropeptides in the brain is challenging since it is primarily composed of lipids 






To improve signal sensitivity, a tissue washing method using organic solvents traditionally used 
for lipid extraction was adopted from Seeley and colleagues (Seeley et al., 2008) and applied to 
this aim of the study.  Four separate solvents were prepared and separate tissue samples from a 
spare mouse were submerged in the following solvents for 30s each: 
1) 70% isopropanol followed by 95% isopropanol (Figure 14) 
2) 70% ethanol followed by 90% ethanol + 9% acetic acid (Figure 15) 
3) 70% methanol followed by 95% methanol (Figure 16) 
4) 2 X 100% xylene (Figure 17) 
The 1374 m/z peak is highlighted in figures 14-17 to clarify the intensity differences of the 
organic solvent treatments.  While the 1350 m/z peak was also included in the chemical treatment 
analysis, it was not highlighted in figures 14-17 since the intensity differences of a single selected 
peak are displayed with an enhanced clarity rather than multiple selected peaks (Flex Imaging 2.1 
User Manual, 2008).  After MALDI-TOF imaging analysis, our data suggested that the 70% 








Figure 14:  MALDI-TOF mass spectra of a 70% isopropanol followed by a 95% isopropanol 
treated mouse brain section (12 μm) recorded in linear positive-ion mode.  The 1374 m/z peak is 
highlighted with a vertical red line in the spectrum display.  Right upper panel represents the 
whole tissue MALDI image.  The intensity of the 1374 m/z peak is denoted by the intensity 








Figure 15:  MALDI-TOF mass spectra of a 70% ethanol followed by a 90% ethanol + 9% acetic 
acid treated mouse brain section (12 μm) recorded in linear positive-ion mode.  The 1374 m/z 
peak is highlighted with a vertical red line in the spectrum display.  Right upper panel represents 
the whole tissue MALDI image. 
 
Figure 16:  MALDI-TOF mass spectra of a 70% methanol followed by 95% methanol treated 





highlighted with a vertical red line in the spectrum display.  Right upper panel represents the 
whole tissue MALDI image. 
 
Figure 17:  MALDI-TOF mass spectra of a 2 X 100% xylene treated mouse brain section (12 
μm) recorded in linear positive-ion mode.  The 1374 m/z peak is highlighted with a vertical red 








Figure 18:  MALDI-TOF mass spectra of an untreated mouse brain section (12 μm) recorded in 
linear positive-ion mode.  The area where the 1374 m/z peak would be is highlighted with a 








Figure 19:  Average number of peak variations recorded from the MALDI-TOF MS in linear 
positive-ion mode acquired from mouse brain sections washed or not washed for 30s with 
different solvent systems in the m/z range from 1350 to 1374.  Isopropanol:  70% isopropanol 
followed by 95% isopropanol; Acetic Acid:  70% ethanol followed by 90% ethanol + 9% acetic 
acid; Methanol:  70% methanol followed by 95% methanol; Xylene:  2 X 100% xylene;  
Untreated:  Sections were not treated with an organic solvent.  Sections desiccated for 45 min at 
21°C before application of the matrix. 
MALDI Imaging for Endogenous Biomarkers 
 After determining that the isopropanol wash yielded the greatest signal sensitivity, 
proteomic profiles in the m/z range of 1000 to 5000 were generated for control and treated 
animals with a Bruker Autoflex III MALDI-TOF/TOF mass spectrometer (Figures 20-24).  The 
functional vacuum pressure (8X10-7 mbar) of the reflectron flight tube could not be obtained due 






mass spectra were recorded in linear positive-ion mode for method development purposes only.  
The 1835 m/z peak is shown as a representative peak in figures 20-24 since it displayed the most 
noticeable change in intensity across control and treated animals.  However, the differences of 
intensity and localization of the 1835 m/z peaks across treatment groups were not quantified due 
to the presence of broad peaks with resolving power inaccuracies. 
 
Figure 20:  MALDI-TOF mass spectra of a saline treated mouse brain section (12 μm) recorded 
in linear positive-ion mode.  The 1835 m/z peak is highlighted with a vertical red line in the 




MALDI image.  The intensity of the 1835 m/z peak is denoted by the intensity legend.  Scale bar 
represents 5mm. 
 
Figure 21:  MALDI-TOF mass spectra of a 1.5 mg/kg CBDP treated mouse brain section (12 
μm) recorded in linear positive-ion mode.  The 1835 m/z peak is highlighted with a vertical red 
line in the spectrum display.  Right upper panel represents the raw whole tissue image adjacent to 






Figure 22:  MALDI-TOF mass spectra of a 1.5mg/kg CBDP + 46µg/kg sarin treated mouse brain 
section (12 μm) recorded in linear positive-ion mode.  The 1835 m/z peak is highlighted with a 
vertical red line in the spectrum display.  Right upper panel represents the raw whole tissue image 
adjacent to its MALDI image.     
 
Figure 23:  MALDI-TOF mass spectra of a 1.5mg/kg CBDP + 4µg/kg sarin + 20mg/kg Q-VD-





peak is highlighted with a vertical red line in the spectrum display.  Right upper panel represents 
the raw whole tissue image adjacent to its MALDI image. 
 
Figure 24:  MALDI-TOF mass spectra of a blank section on a conductive glass slide recorded in 
linear positive-ion mode.  The area where the 1835 m/z peak would be is highlighted with a 
vertical red line in the spectrum display.  Right upper panel represents the raw blank image 
adjacent to its MALDI image. 
GFAP Immunofluorescent Staining  
 GFAP is an intermediate filament protein of astroglia and is a marker for neuronal injury.  
An increase in GFAP expression is an indication of trauma to these cells.  GFAP staining in the 
dendate gyrus from negative control mice (Figure 25, A1-A3) showed no positive staining 
compared to CBDP (Figure 25, B1-B3), sarin (Figure 25, C1-C3), and Q-VD-OPh (Figure 25, 
D1-D3) treated mice.  Analysis of cell counts in the dendate gyrus of mice revealed an upward 
trend in GFAP expression following sarin injection compared to CBDP and Q-VD-OPh treated 





expression than sarin treated animals but an upward trend in GFAP expression than CBDP treated 
animals.   
 GFAP staining in the CA2-CA3 sub-region from negative control mice (Figure 27, A1-
A3) showed no positive staining compared to CBDP (Figure 27, B1-B3), sarin (Figure 27, C1-
C3), and Q-VD-OPh (Figure 27, D1-D3) treated mice.  Analysis of cell counts in the CA2-CA3 
sub-region of mice revealed an upward trend in GFAP expression following sarin injection 
compared to CBDP and Q-VD-OPh treated animals (Figure 28).  Additionally, Q-VD-OPh 
treated mice showed a downward trend in GFAP expression than sarin treated animals but an 
upward trend in GFAP expression than CBDP treated animals.   
 GFAP staining in the piriform cortex from negative control mice (Figure 29, A1-A3) 
showed no positive staining compared to CBDP (Figure 29, B1-B3), sarin (Figure 29, C1-C3), 
and Q-VD-OPh (Figure 29, D1-D3) treated mice.  Statistical analysis of cell counts in the 
piriform cortex of mice revealed an upward trend in GFAP expression following sarin injection 
compared to CBDP and Q-VD-OPh treated animals (Figure 30).  Additionally, Q-VD-OPh 
treated mice showed a downward trend in GFAP expression than sarin treated animals but an 
upward trend in GFAP expression than CBDP treated animals.   
 GFAP staining in the amygdala from negative control mice (Figure 31, A1-A3) showed 
no positive staining compared to CBDP (Figure 31, B1-B3), sarin (Figure 31, C1-C3), and Q-
VD-OPh (Figure 31, D1-D3) treated mice.  Statistical analysis of cell counts in the amygdala of 
mice revealed an upward trend in GFAP expression following sarin injection compared to CBDP 
and Q-VD-OPh treated animals (Figure 32).  Additionally, Q-VD-OPh treated mice showed a 
downward trend in GFAP expression than sarin treated animals but a nominal upward trend in 
GFAP expression than CBDP treated animals.   
 GFAP staining in the hypothalamus from negative control mice (Figure 33, A1-A3) 





and Q-VD-OPh (Figure 33, D1-D3) treated mice.  Statistical analysis of cell counts in the 
hypothalamus of mice revealed an upward trend in GFAP expression following sarin injection 
compared to CBDP and Q-VD-OPh treated animals (Figure 34).  Additionally, Q-VD-OPh 
treated mice showed a downward trend in GFAP expression than sarin treated animals but an 







Figure 25:  Alterations of GFAP expression in the dendate gyrus at 2 days following exposure 
across treatment groups.  A1-A3 is an example from a negative control for the staining protocol; 
A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg 
CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a 
mouse treated with 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of 






Figure 26:  Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641 
x 479 µm2) in the dendate gyrus of mice across different treatment groups.  CBDP mice received 
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline, 
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.  
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.  
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2).  F2,4= 







Figure 27:  Alterations of GFAP expression in the CA2-CA3 region at 2 days following exposure 
across treatment groups.  A1-A3 is an example from a negative control for the staining protocol; 
A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg 
CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a 
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of 






Figure 28:  Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641 
x 479 µm2) in the CA2-CA3 region of mice across different treatment groups.  CBDP mice 
received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin 
+ saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.  
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.  
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2).  F2,4= 









Figure 29:  Alterations of GFAP expression in the piriform cortex at 2 days following exposure 
across treatment groups.  A1-A3 is an example from a negative control for the staining protocol; 
A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg 
CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a 
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of 






Figure 30:  Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641 
x 479 µm2) in the piriform cortex of mice across different treatment groups.  CBDP mice received 
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline, 
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.  
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.  
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2).  F2,4= 










Figure 31:  Alterations of GFAP expression in the amygdala at 2 days following exposure across 
treatment groups.  A1-A3 is an example from a negative control for the staining protocol; A3, is 
an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg CBDP; B3, 
is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 1.5mg/kg CBDP + 
46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of D1 and D2.  






Figure 32:  Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641 
x 479 µm2) in the amygdala of mice across different treatment groups.  CBDP mice received 
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline, 
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.  
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.  
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2).  F2,4= 










Figure 33:  Alterations of GFAP expression in the hypothalamus at 2 days following exposure 
across treatment groups.  A1-A3 is an example from a negative control for the staining protocol; 
A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg 
CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a 
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of 






Figure 34:  Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641 
x 479 µm2) in the hypothalamus of mice across different treatment groups.  CBDP mice received 
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline, 
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.  
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.  
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2).  F2,4= 
3.503; A p-value < 0.05 was considered significant. 
NF-κB/p50-50 Immunofluorescent Staining 
 NF-κB is present in neurons and glial cells in the CNS and plays a crucial role in 
neuroinflammatory and immunological responses.  Inactive NFκB dimers are localized in the 
cytoplasm by IκB whereas active NFκB/p50-p50 homodimers and  NFκB/p50-p65 heterodimers  
are present in the nucleus.  It was unknown which dimer would be predominantly activated in this 
study.  We used a primary NFκB/p50 antibody to label active anti-inflammatory NFκB/p50-p50 





antibody also labels the NFκB/p105 precursor complex that holds the inactive NFκB/p50-50 
dimer in the cytoplasm (Santa Cruz Biotechnology, 2010).  Therefore, we analyzed the ratio of 
nuclear versus cytoplasmic NFκB/p50-p50 in order to evaluate if sarin or Q-VD-OPh had an 
active, inhibitory, or null effect in causing the nuclear translocation of NFκB/p50-p50 in our 
study.    
 An increase in nuclear versus cytoplasmic NFκB/p50-50 expression is an indication of 
anti-inflammatory gene transcription thereby inducing a cellular environment promoting 
apoptosis.  Positive NFκB p50 staining in the dendate gyrus of control and treated animals was 
not quantified due to nonspecific positive staining in negative control tissue sections.  However, 
NFκB p50 staining in the CA2-CA3 regions from negative control mice (Figure 35, A1-A3) 
showed no positive staining compared to CBDP (Figure 35, B1-B3), sarin (Figure 35, C1-C3), 
and Q-VD-OPh (Figure 35, D1-D3) treated mice.  Statistical analysis of cell counts in the CA2-
CA3 sub-region of mice revealed a significant increase in nuclear NFκB p50 expression 
following Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 36).  
Additionally, CBDP treated mice showed a nominal increase in nuclear NFκB p50 expression 
than sarin treated animals.   
 NFκB p50 staining in the piriform cortex from negative control mice (Figure 37, A1-A3) 
showed no positive staining compared to CBDP (Figure 37, B1-B3), sarin (Figure 37, C1-C3), 
and Q-VD-OPh (Figure 37, D1-D3) treated mice.  Statistical analysis of cell counts in the 
piriform cortex of mice revealed a significant increase in nuclear NFκB p50 expression following 
Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 38).  Additionally, 
CBDP treated mice showed a nominal decrease in nuclear NFκB p50 expression than sarin 
treated animals. 
 NFκB p50 staining in the amygdala from negative control mice (Figure 39, A1-A3) 





and Q-VD-OPh (Figure 39, D1-D3) treated mice.  Statistical analysis of cell counts in the 
amygdala of mice revealed a significant increase in nuclear NFκB p50 expression following Q-
VD-OPh injection compared to CBDP and sarin treated animals (Figure 40).  Additionally, 
CBDP treated mice showed a nominal increase in nuclear NFκB p50 expression than sarin treated 
animals. 
 NFκB p50 staining in the hypothalamus from negative control mice (Figure 41, A1-A3) 
showed no positive staining compared to CBDP (Figure 41, B1-B3), sarin (Figure 41, C1-C3), 
and Q-VD-OPh (Figure 41, D1-D3) treated mice.  Statistical analysis of cell counts in the 
hypothalamus of mice revealed a significant increase in nuclear NFκB p50 expression following 
Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 42).  Additionally, 







Figure 35:  Alterations of NF-κB p50 expression in the CA2-CA3 region at 2 days following 
exposure across treatment groups.  A1-A3 is an example from a negative control for the staining 
protocol; A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 
1.5mg/kg CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated 
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example 
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an 






Figure 36:  Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive 
cells in µm2 per unit area (321 x 240 µm2) in the CA2-CA3 region of mice across different 
treatment groups.  CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 
1.5 mg/kg CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 
46µg/kg sarin + 20mg/kg Q-VD-OPh.  Animals were treated with a single dose of each treatment 
and analyzed 2 days post exposure.  Each bar represents the mean ± S.D. per group (CBDP, n=2; 









Figure 37:  Alterations of NF-κB p50 expression in the piriform cortex at 2 days following 
exposure across treatment groups.  A1-A3 is an example from a negative control for the staining 
protocol; A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 
1.5mg/kg CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated 
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example 
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an 






Figure 38:  Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive 
cells in µm2 per unit area (321 x 240 µm2) in the piriform cortex of mice across different 
treatment groups.  CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 
1.5 mg/kg CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 
46µg/kg sarin + 20mg/kg Q-VD-OPh.  Animals were treated with a single dose of each treatment 
and analyzed 2 days post exposure.  Each bar represents the mean ± S.D. per group (CBDP, n=2; 












Figure 39:  Alterations of NF-κB p50 expression in the amygdala at 2 days following exposure 
across treatment groups.  A1-A3 is an example from a negative control for the staining protocol; 
A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 1.5mg/kg 
CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated with 
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example from a 
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of 






Figure 40:  Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive 
cells in µm2 per unit area (321 x 240 µm2) in the amygdala of mice across different treatment 
groups.  CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg 
CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin 
+ 20mg/kg Q-VD-OPh.  Animals were treated with a single dose of each treatment and analyzed 
2 days post exposure.  Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-










Figure 41:  Alterations of NF-κB p50 expression in the hypothalamus at 2 days following 
exposure across treatment groups.  A1-A3 is an example from a negative control for the staining 
protocol; A3, is an overlay of A1 and A2.  B1-B3 is an example from a mouse treated with 
1.5mg/kg CBDP; B3, is an overlay of B1 and B2.  C1-C3 is an example from a mouse treated 
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2.  D1-D3 is an example 
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an 







Figure 42:  Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive 
cells in µm2 per unit area (321 x 240 µm2) in the hypothalamus of mice across different treatment 
groups.  CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg 
CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin 
+ 20mg/kg Q-VD-OPh.  Animals were treated with a single dose of each treatment and analyzed 
2 days post exposure.  Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-




 The main objective of this study was to determine if an in-vivo caspase inhibitor Q-VD-
OPh, could attenuate sarin induced neuroinflammation and neurodegeneration in specific brain 
regions of mice at a two-day time point.  The aim of the study was two-fold:  1) Establish 
neuroinflammatory and neurodegenerative markers of sarin exposure; and 2) Determine if Q-VD-
OPh could attenuate sarin induced prolonged or progressive neuroinflammation and 
neurodegeneration.  We tested the hypothesis using three specific techniques:  MALDI Imaging 
of whole brain tissues for endogenous OP-biomarkers; GFAP immunofluroescent staining in 
brain regions for neuronal injury; and NF-κB p50 immunofluorescent staining in brain regions for 
a promotion or lack of apoptotic induced cell death.   
MALDI Imaging 
 It was originally intended to record tissue sample analytes in reflectron positive-ion mode 
in order to avoid the production of mass spectra with poor resolution due to peak width 
broadening.  For the reflectron to be operational, a turbomolecular vacuum pump pressurizes the 
flight tube to 8X10-7 mbar in order to redirect ions to the reflector detector (Autoflex Operator 
Manual, 2011).  Inherent hardware abnormalities with the reflectron turbomolecular vacuum 
pump prevented the reflectron ion flight tube to reach nominal pressure.  In contrast to the 
reflectron vacuum pump system, the linear vacuum pump system is operational at a pressure of 
1X10-2 mbar in order to accelerate ions through a linear flight tube (Autoflex Operator Manual, 
2011).  Thus, all tissue sample mass spectra were recorded in linear positive-ion mode to 







 The application of organic solvents to tissues before MALDI-TOF analysis is a widely 
accepted practice.  For instance, Lemaire and colleagues subjected tissue sections from rat brains 
to variety of organic solvents before MALDI analysis after noting untreated tissue sections 
demonstrated poor signal intensities (2006).  They concluded that chloroform and xylene 
increased the signal intensity of a number of peptides in the m/z range of 500-1000 among all 
tested solvents (Lemaire et al., 2006).  The chemical treatment of tissue sections to enhance signal 
quality of low molecular weight neuropeptides (less than 5000 m/z) is not limited to brain tissue.  
For instance, Leinweber and colleagues (2008) subjected rodent kidney tissue sections to organic 
solvent layers before analyzing high molecular weight peptides (greater than 5000 m/z).  After 
placing kidney sections on top of a sinapinic acid (SA) dissolved in 90% ethanol + 0.5% TX-100, 
they verified this treatment yielded the greatest signal intensity of peptides in the 10,000 to 
50,000 m/z range (Leinweber et al., 2008).   
 In our study, we observed that treated tissue sections with organic washes yielded a 
greater signal sensitivity compared to untreated tissue sections.  However, the spectra observed in 
our chemically treated spare sections and our experimental sections were poor due to the presence 
of broad peaks.  A more detailed inspection of our MALDI-TOF hardware would have revealed 
the reflectron turbomolecular pump was not at operational capacity.  Despite our limitations of 
utilizing MALDI-TOF linear positive-ion mode during the in-situ analysis of mouse brain tissue 
sections, we were able to determine that it is necessary to apply an organic solvent to the sections 
before analyzing endogenous neuropeptides in the 1000 to 5000 m/z range.  Further pursuit of this 





GFAP and NF-κB Immunofluorescent Staining  
 The toxic by-products of sub-lethal sarin exposure can cause damage to surrounding 
tissue.  GFAP expression is a marker for neuronal injury and nuclear NF-κB/p50-p50 expression 
is a marker for the transcription of anti-inflammaotry cytokines and hence, inducing a cellular 
environment promoting apoptotic cell death.  It was hypothesized that Q-VD-OPh will act as a 
neuroprotectant by suppressing neuronal injury and may activate NF-κB p50 translocation into 
the nucleus.  To test this hypothesis, it was originally intended to analyze the dendate gyrus, 
CA2-CA3 sub-region, piriform cortex, amygdala, and hypothalamus of mice in saline, CBDP, 
sarin, and Q-VD-OPh treated groups (n=3) with GFAP and NF-κB p50 immunofluorescent 
stains.  Increased GFAP staining with decreased nuclear NF-κB p50 expression in sarin treated 
animals would indicate a cellular environment favoring neuronal injury and transcription of anti-
inflammatory cytokines.  On the contrary, decreased GFAP staining with increased nuclear NF-
κB p50 expression in Q-VD-OPh treated animals would indicate a cellular environment favoring 
neuroprotection and transcription of anti-inflammatory cytokines.   
 Despite the problems presented during tissue sectioning and collection, we were able to 
obtain enough viable tissue to evaluate the significance that not all GFAP and NF-κB p50 stained 
sections were the same across (saline, n=1; CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2) treatment 
groups.  Since the saline group presented a low sample number, we quantified and compared the 
differences in GFAP and NF-κB p50 expression from CBDP, sarin, and Q-VD-OPh treated 
animals.  While we were only able to observe positive GFAP staining in the dendate gyrus, we 
were able to identify positive GFAP and NF-κB p50 staining in the CA2-CA3 sub-regions, 
piriform cortex, amygdala, and hypothalamus from representative animals. 
 A general trend in GFAP and nuclear NF-κB p50 expression was observed in specific 
brain regions of mice across treatment groups.  GFAP expression in the dendate gyrus, CA2-CA3 





However, no discernable difference in GFAP expression was observed in the piriform cortex and 
amygdala in CBDP and Q-VD-OPh treated animals.  In contrast, nuclear NF-κB p50 expression 
in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of CBDP and Q-VD-
OPh treated mice presented no genuine difference in staining.  In contrast, nuclear NF-κB p50 
expression in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of Q-VD-
OPh treated animals showed an upward trend compared to sarin and CBDP treated animals.  Most 
importantly, in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of sarin 
treated animals, there was an upward trend in GFAP expression, and a downward trend in NF-κB 
p50 expression compared to Q-VD-OPh treated animals.   
 The most critical finding in the present study was that GFAP and nuclear NF-κB p50 
expression in sarin and Q-VD-OPh treated animals showed opposing trends in expression across 
all brain regions examined.  The upward trend in GFAP expression and downward trend in 
nuclear NF-κB p50 expression suggests that sub-lethal sarin exposure is inducing neuronal injury 
in a proinflammatory and anti-apoptotic cellular environment.  Furthermore, the downward trend 
in GFAP expression and upward trend in nuclear NF-κB p50 expression suggests that Q-VD-OPh 
is inducing neuroprotection in an anti-inflammatory and pro-apoptotic cellular environment.  
These observations lead to the reasoning that Q-VD-OPh may be effecting the expression of NF-
κB/p50-p50 and NF-κB/p50-p65 concomitantly. 
 The point at which a cell becomes pro-apoptotic or anti-apoptotic during OP exposure is 
dependent on the expression of active NF-κB/p50-p50 and NF-κB/p50-p65 dimers.  Active NF-
κB dimers exist in a dynamic cross talk with ROS, caspases, and JNK involved in various signal 
transduction pathways (Figure 43) (Bubici et al., 2006).  OP’s have been shown to disrupt normal 
signal transduction pathways regulated by MAPKs (mitogen-activated protein kinases) that lead 
to abnormal transcription of intermediate filaments in the CNS (Caughlan et al., 2004; 





2002).  JNK (c-Jun N-terminal kinase) is a member of the MAPK pathway that is activated in 
response to numerous extracellular stimuli and different forms of intracellular stress 
(Dhanasekaran and Reddy 2008).  OP’s have shown to induce ROS production yet the 
mechanism remains unknown.  However, the positioning of JNK downstream of ROS may 
provide an indication to the induction of apoptosis following OP exposure (Matsuzawa and Ichijo 
2005; Pham et al., 2004).     
 
Figure 43:  NF-κB dimers in a dynamic cross talk with JNK, ROS, and caspases.  Active NF-κB 
dimers play a central role in the promotion and inhibition of pro-apoptotic molecular players.  
Further elucidation as to which active dimer is primarily activated is needed in order to determine 
if Q-VD-OPh is an optimal therapeutic in attenuating sub-lethal nerve agent induced 
neuropathies. 
 The observation of an upward trend in nuclear NF-κB/p-50-50 expression in Q-VD-OPh 





mg/kg of Q-VD-OPh had no effect when administered in adult male C57BL/6J mice (Liu et al., 
2009).  On the contrary, a 20 mg/kg Q-VD-OPh administration in adult female C57BL/6J mice 
was neuroprotective, consistent with evidence that female mice superbly benefited from Q-VD-
OPh therapy (Liu et al., 2009; Renolleau et al., 2007).  If adult female C57BL/6J mice had been 
used in this study, more significant results may have been observed.  In addition, a higher number 
of animals would validate the hypothesis that Q-VD-OPh is neuroprotective when administered 
following sub-lethal sarin exposure.   
Future Research 
 Additional staining with antibodies against additional neuroinflammatory cytokines, e.g., 
IL-6, IL-10, IL-1β, TNF-α, and PGE2 would provide a baseline of neuroinflammation or lack 
thereof, in mice exposed to sub-lethal amounts of sarin.  It would also be beneficial to stain with 
antibodies against NF-κB/p-50-50 homodimers and NF-κB/p-50-65 heterodimers in order to 
determine which dimer is predominantly activated following sub-lethal sarin exposure.  Further 
staining with antibodies against activated caspase 3, 8, and 9 would determine apoptotic cell 
death in the brain and provide an essential complement to neuroinflammatory cytokine staining. 
 A more extensive study harvesting the collection of tissue sections at multiple time points 
(8 hrs, 24 hrs, two days, and two weeks) following sarin exposure and Q-VD-OPh administration 
would allow a more thorough understanding of OP-induced delayed neurodegeneration and 
neuroinflammation.  It would be beneficial to include more time points to in order to determine 
the optimal period of NF-κB/p-50-50 or NF-κB/p-50-65 activation.  Most importantly, the use of 
adult female C57BL/6J mice may provide as a better model for studying the ability of Q-VD-OPh 
to attenuate neurodegeneration and neuroinflammation following sub-lethal sarin exposure.  
Additionally, ensuring the generation of proteomic profiles from sarin and Q-VD-OPh tissue 
sections is captured in reflectron mode would allow for the future localization of sarin and Q-VD-






 Sarin is an OP ester that remains an active threat to military personnel and more 
importantly, a vulnerable civilian population.  It is only recently that current research efforts are 
pursuing new therapies to counter act OP poisoning for current treatments do not address any of 
the long-term side effects associated with nerve agent exposure.  The investigation of new 
therapies starts with our current understanding of delayed OP induced neuropathies.  Soldiers and 
civilians of past nerve agent attacks developed progressive declines in cognitive ability evident in 
studies linking neurohistopathological lesions to brain regions responsible for the regulation of 
memories, mood, judgment, emotions, and learning (Spradling, 2011).  The delayed effects 
persisted even after the administration of CANA-MARK I prophylactics within the crucial 40 
minute window they remain effective.  This opened a window to innovative research paradigms 
that extended beyond the emphasis of regenerating AChE and managing seizures.  
 The present pilot study focused on the capability of an in-vivo caspase inhibitor to 
attenuate sarin-induced, prolonged or progressive CNS neuroinflammation and 
neurodegeneration in adult male C57BL/6J mice at a two-day time point.  Mice were subjected to 
a dosing sequence that mimics chronic OP toxicity in humans via the injection of 1.5 mg/kg 
CBDP before a 0.5 LD50 injection of sarin.  To ensure that our caspase inhibitor provided 
neuroprotection beyond the limitations of CANA-MARK-1 treatments, mice received a 20 mg/kg 
injection of Q-VD-OPh 40 minutes after sarin injections.  MALDI imaging of whole brain tissue 
sections for endogenous OP-biomarkers captured in linear positive ion mode presented spectra 
with poor mass resolution and broad peaks.  Most notably however, the staining methods for 
GFAP and nuclear NF-κB p50 expression successfully labeled positive cells in all five brain 
regions examined with the exception of NF-κB p50 staining in the dendate gyrus.  
 The discovery that GFAP and nuclear NF-κB p50 expression in sarin and Q-VD-OPh 






additional neurodegenerative and neuroinflammatory alterations following sub-lethal nerve agent 
exposure.  For instance, active NF-κB dimers exist in a dynamic cross talk with JNK, ROS, and 
caspases and play a central role in the promotion and inhibition of pro-apoptotic molecular 
players (Bubici, 2006).  Likewise, GFAP is an indicator for neuronal injury that upon activation 
forms a glial scar around damaged tissue (Sofroniew and Vinters 2010).  While further validation 
is warranted, the upward trend in GFAP expression and downward trend in nuclear NF-κB p50 
expression suggests that sub-lethal sarin exposure is inducing neuronal injury in a 
proinflammatory and anti-apoptotic cellular environment.  On the contrary, the downward trend 
in GFAP expression and upward trend in nuclear NF-κB p50 expression suggests that Q-VD-OPh 
is inducing neuroprotection in an anti-inflammatory and pro-apoptotic cellular environment.  
Future research efforts would validate the neuroprotective ability of Q-VD-OPh to attenuate the 
delayed type neuropathies induced by sub-lethal nerve agent exposure.
 
 
V.  Appendix 
Treatment Animal # DG CA2-CA3 Pir Amy Hypo 
Saline 326 153 148 28 17 94 
Avg. N/A N/A N/A N/A N/A N/A 
CBDP 
330 186 191 27 62 118 
331 113 105 19 17 66 
Avg. (n=2) 149.5 148 23 39.5 92 
Sarin 
334 316 328 161 130 185 
335 206 150 173 87 183 
336 289 234 53 77 204 
Avg. (n=3) 270.3 237.3 129 98 190.7 
QVD 
339 261 236 54 48 185 
341 125 130 42 34 82 
Avg. (n=2) 193 183 96 41 133.5 
 
Table 1.  GFAP immunofluorescent staining:  This table summarizes the raw number of 
positively labeled GFAP cells from each brain region assessed for statistical analysis.  Negative 
controls were stained to confirm the staining method was performed properly; however, counts 
were not included in the analysis.  Counts from one section per animal were averaged to obtain a 
mean cell count for each region.  Cell counts from saline regions were disregarded because of a 
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Saline  326 70 7 0.100 14 2 0.143 62 7 0.113 69 7 0.101 
Avg. N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CBDP 
330 39 6 0.154 34 5 0.147 16 2 0.125 28 5 0.179 
331 21 3 0.143 22 3 0.136 14 2 0.143 27 4 0.148 
Avg. (n=2) 30 4.5 0.149 28 4 0.142 15 2 0.134 27.5 4.5 0.164 
Sarin 
334 48 5 0.104 32 5 0.156 27 4 0.148 23 3 0.130 
335 27 4 0.148 16 2 0.125 18 2 0.111 19 3 0.158 
336 29 4 0.138 20 3 0.150 15 2 0.133 16 3 0.188 
Avg. (n=3) 34.7 4.3 0.130 22.7 3.3 0.144 20 2.7 0.131 19.3 3 0.159 
QVD 
339 60 22 0.367 57 21 0.368 33 10 0.303 58 18 0.310 
341 24 6 0.250 23 10 0.435 13 5 0.385 19 6 0.316 
Avg. (n=2) 42 14 0.309 40 15.5 0.402 23 7.5 0.344 38.5 12 0.313 
 
Table 2.  NF-κB p50 immunofluorescent staining:  This table summarizes the raw ratio of 
nuclear (n) versus cytoplasmic (c) positively labeled cells from each brain region assessed for 
statistical analysis.  Negative controls were stained to confirm the staining method was performed 






animal were averaged to obtain a mean ratio of nuclear versus cytoplasmic NF-κB p50 for each 
region.  Cell counts from saline regions were disregarded because of a small sample size (n=1).
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